CCL2 and metabolic dysfunction-associated steatohepatitis: Moreover, we have recently discovered an anti-inflammatory role of SHP during the development of nonalcoholic steatohepatitis (NASH), where the loss of Shp in hepatocytes triggers nuclear factor kappa B (NF-κB) activation and the release of chemokine (C-C motif) ligand 2 (CCL2), exacerbating liver inflammation and fibrosis [28,29].